期刊文献+

肝纤维化程度对行腹腔镜下ALPPS术巨块型原发性肝癌患者临床指标的影响 被引量:6

Influence of Hepatic Fibrosis Degree on Remnant Liver Volume,Operation Interval Time and Liver Function Index of Patients with Giant Block Type Liver Cancer with ALPPS by Laparoscopic Resection
下载PDF
导出
摘要 目的:探讨肝纤维化程度对行腹腔镜下ALPPS术巨块型原发性肝癌患者残肝体积、手术间隔时间及肝功能指标的影响。方法:选取我院2013年4月~2015年4月收治合并肝硬化原发性肝癌行腹腔镜下ALPPS术患者共42例,其中,轻中度肝纤维化患者共28例设为A组,重度肝纤维化患者共14例设为B组;比较两组患者手术完成率,残肝体积增加情况、手术间隔时间及手术前后肝功能指标等。结果:A组患者手术完成率显著高于B组,差异具有显著性(P〈0.05);A组患者残肝体积增加情况明显优于B组,差异具有显著性(P〈0.05);A组患者手术间隔时间明显短于B组,差异具有显著性(P〈0.05);同时A组患者术后24h肝功能指标均明显优于B组,差异具有显著性(P〈0.05)。结论:相较于重度肝纤维化,合并轻中度肝纤维化巨块型原发性肝癌患者行腹腔镜下ALPPS术治疗在增加残肝体积、缩短手术间隔及保护肝脏功能方面优势明显。 Objective: To investigate the influence of hepatic fibrosis degree on remnant liver volume,operation intervaltime and liver function index of patients with giant block type liver cancer with ALPPS by laparoscopic resection.Methods:42patients with giant block type liver cancer with ALPPS by laparoscopic resection were chosen in the April 2013 to April 2014 inour hospital and divided into both group including A group (28 patients) with shepatic fibrosis for mild and moderate degree andB group (14 patients) with hepatic fibrosis for severe degree;and the operation completion rate,the increasing degree of residualliver volume,operation interval time and liver function indexes before and after surgery of both groups were compared.Results:The operation completion rate of A group was significantly higher than B group(P〈0.05).The increasing degree of residual livervolume of A group was significantly better than B group(P〈0.05).The operation interval time of A group was significantly shorterthan B group(P〈0.05).The liver function indexes in 24h after surgery of A groups was significantly better than B group(P〈0.05).Conclusion:Compared with hepatic fibrosis for severe degree,ALPPS by laparoscopic resection in treatment of patients withgiant block type liver cancer and shepatic fibrosis for mild and moderate degree can efficiently increase the volume of remnantliver,shorten the operation interval time and protect the liver function.
出处 《中国医药导刊》 2016年第6期602-603,606,共3页 Chinese Journal of Medicinal Guide
关键词 肝纤维化 ALPPS 巨块型原发性肝癌 肝功能 Hepatic fibrosis ALPPS Giant block type primary hepatic cancer Liver function
  • 相关文献

参考文献11

  • 1陈建国.中国肝癌发病趋势和一级预防[J].临床肝胆病杂志,2012,28(4):256-260. 被引量:111
  • 2Schadde E,Schnitzbauer AA,Tschuor C,et al.Systematic Reviewand Meta-Analysis of Feasibility,Safety,and Efficacy of a NovelProcedure:Associating Liver Partition and Portal Vein Ligation forStaged Hepatectomy[J].Ann Surg Oncol,2015,22(9): 3109-3120.
  • 3Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidenceand mortality worldwide:sources,methods and major patterns inGLOBOCAN 2012[J].Int J Cancer,2015,136(5):359-386.
  • 4周俭,王征,孙健,肖永胜,樊嘉,汤钊猷.联合肝脏离断和门静脉结扎的二步肝切除术[J].中华消化外科杂志,2013,12(7):485-489. 被引量:73
  • 5Dokmak S,Belghiti J.Which limits to the "ALPPS" approach?[J].Ann Surg,2012,256(3):16-17.
  • 6R o b l e s R,P a r r i l l a P,L o p e z - C o n e s a A,e t a l.T o u r n i q u e tmodification of the associating liver partition and portalligation for staged hepatectomy procedure[J].Br J Surg,2014,101(9):1129-1134.
  • 7Aloia TA,Vauthey JN.Associating liver partition and portal veinligation for staged hepatectomy(ALPPS):what is gained and whatis lost-[J].Ann Surg,2012,256(3):16-19.
  • 8联合肝脏离断和门静脉结扎二步肝切除术在肝癌治疗中应用[J].中国实用外科杂志,2014,34(8):726-731. 被引量:10
  • 9Schadde E,Ardiles V,Slankamenac K,et al.ALPPS offers a better chanceof complete resection in patients with primarily unresectable livertumors compared with conventional-staged hepatectomies:results of amulticenter analysis [J].World J Surg,2014,38(6):1510-1519.
  • 10Levi Sandri GB,Lai Q,Rayar M,et al.ALPPS procedure forhepatocellular carcinoma with macrovascular thrombosis: a newopportunity-[J].J Hepatol,2015,62(1):241-242.

二级参考文献54

  • 1陈建国,朱健,张永辉,朱源荣,陆建华.江苏省启东地区1973至2002年肝癌发病率长期趋势的评价[J].中华医学杂志,2005,85(43):3052-3056. 被引量:53
  • 2Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 3Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
  • 4IARC.GLOBOCAN 2008,Cancer incidence and mortalityworldwide in 2008[DB/OL].http://globocan.iarc.fr,2011-8-22.
  • 5Alam N,Robotin M,Baker D.Epidemiology of primary livercancer[J].Cancer Forum,2009,33(2):88-92.
  • 6Hattori M,Fujita Manabu,Ito Y,et al.Use of a population-based cancer registry to calculate twenty-year trends incancer incidence and mortality in Fukui Prefecture[J].J Epi-demiol,2010,20(3):244-252.
  • 7Stuver S,Trichopoulos D.Cancer of the liver and biliary tract[Chapter 12].In:Adami[C]//HO,New York:Oxford Uni-versity Press,2008:308-332.
  • 8Chen JG,Zhang SW.Liver cancer epidemic in China:past,pres-ent and future[J].Semin Cancer Biol,2011,21(1):59-69.
  • 9Sun Z,Lu P,Gail MH,et al.Increased risk of hepatocellularcarcinoma in male hepatitis B surface antigen carriers withchronic hepatitis who have detectable urinary aflatoxin me-tabolite M1[J].Hepatology,1999,30(2):379-383.
  • 10Qian GS,Ross RK,Yu MC,et al.A follow-up study of uri-nary markers of aflatoxin exposure and liver cancer risk inShanghai,People's Republic of China[J].Cancer EpidemiolBiomarkers Prev,1994,3(1):3-10.

共引文献196

同被引文献53

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部